Navigation Links
Amylin Announces Preliminary Results of Annual Meeting of Stockholders
Date:5/27/2009

he Annual Meeting will be announced once they are certified by the Inspector following the customary review and challenge period.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

Forward Looking Statements

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN or exenatide once weekly may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results or achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates or sNDAs for label expansion requests, such as the exenatide once weekly NDA mentioned in this press release, may not be submitted timely or receive FDA approval; risks that our expense reductions will not be as large as we expect; risks that the restructured operations for ex
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Amylin Pharmaceuticals Reports First Quarter Financial Results
8. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
9. Lilly and Amylin Set Date and Time for Conference Call
10. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
11. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Colo. (July 8, 2014) A new study from ... modest improvements, poor oral health remains a major problem ... , "The oral health among Native Americans is abysmal ... rest of the country," said Terrence Batliner, DDS, MBA, ... Research at the School of Public Health. "The number ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Adults with dyslexia are more ... children or teenagers than people who don,t have the ... Dyslexia, which affects up to 10 percent of people, ... 35 percent of adults with this condition said they ... percent of those without dyslexia. "Even after accounting ...
(Date:7/10/2014)... Kristen Fischer HealthDay ... Slimming down may help ease the hot flashes that often ... debilitating for more than 50 percent of menopausal women, said ... and reproductive science at the Icahn School of Medicine at ... menopausal women experience more than 10 hot flashes a day, ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July ... that break out regularly between outspoken celebrities or loudmouth pundits ... relationship, a new study suggests. High amounts of Twitter ... the couple is in a long-term relationship, according to findings ... turn, that friction can lead to cheating and breakups, the ...
Breaking Medicine News(10 mins):Health News:Study finds widespread oral health problems among Navajo 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3
... Patient Care Model Significantly Improves Patient OutcomesEL SEGUNDO, ... provider of kidney care services for those diagnosed ... findings of a study revealing DaVita,s IMPACT(TM) (Incident ... program can significantly reduce mortality rates for new ...
... Pediatric surgeons are able to repair complex heart defects ... but that doesn,t necessarily mean a happy ending for ... great quality of life and others, with the same ... pediatric medical centers throughout the United States shows that ...
... HOUSTON (March 29, 2009) The allergen breathed in by ... MMP7 that activates a cascade of events to prompt an ... College of Medicine ( www.bcm.edu ) in Houston in a ... Immunology . , In particular, MMP7 activates interleukin 25, a ...
... the same for bare metal or drug-eluting devices, study found, ... that stent thrombosis, a blood clot inside a stent, is ... no difference in the clot risk for either drug-eluting ... After a heart attack, many patients undergo a treatment ...
... Health Ltd. affiliate program is the answer for individuals who want to ... benefits as well as demand. ZEO Health has created a risk-free, ... today and find out more about the affiliate program. , ... New ...
... Michael Harbut, M.D., MPH, co-director of the National ... Barbara Ann Karmanos Cancer Institute in Detroit, MI, and ... Wayne State University , announced the use of ... asbestos-related lung disease. The announcement was made at the ...
Cached Medicine News:Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 2Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 3Health News:Physicians mending broken hearts 2Health News:No Increase in Clots With Drug-Eluting Stents 2Health News:No Increase in Clots With Drug-Eluting Stents 3Health News:ZEO Health's New Program Offers Answer for Those Looking for Income 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 3
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... VRUS ), a clinical stage pharmaceutical company ... treat viral,infections, reported unaudited financial results for the ... Pharmasset reported a net loss,attributable to common stockholders ... first fiscal quarter of 2008, as compared to ...
... Software & Database Developed in West ... Treatment Options, VENLO, Netherlands and GRAND RAPIDS, ... (CMM) today announced the formation of a,collaborative effort ... Prime Standard: QIA) to support research focused on ...
Cached Medicine Technology:Pharmasset Reports First Fiscal Quarter 2008 Financial Results 2Pharmasset Reports First Fiscal Quarter 2008 Financial Results 3Pharmasset Reports First Fiscal Quarter 2008 Financial Results 4Pharmasset Reports First Fiscal Quarter 2008 Financial Results 5Pharmasset Reports First Fiscal Quarter 2008 Financial Results 6Pharmasset Reports First Fiscal Quarter 2008 Financial Results 7Pharmasset Reports First Fiscal Quarter 2008 Financial Results 8QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 2QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 3QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 4
Nitinol Flat Wire Basket...
A breakaway microwell EIA for the detection of toxins produced by Enterohemorrhagic E. coli...
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Medicine Products: